Biosion Inks Exclusive Deal With Aclaris For Worldwide Rights To BSI-045B And BSI-502
18/11 15:09
(RTTNews) - Biosion, Inc., a R&D stage biotechnology company, announced Monday that it has entered into an exclusive license agreement with Aclaris Therapeutics, Inc. (ACRS) for worldwide rights, excluding Greater China, to BSI-045B and BSI-502....